体外膜肺氧合：十年经验
Extracorporeal membrane oxygenation: a ten-year experience.
作者信息
Mols G, Loop T, Geiger K, Farthmann E, Benzing A
机构信息
Department of Anesthesiology and Critical Care Medicine, University of Freiburg, Freiburg, Germany.
出版信息
Am J Surg. 2000 Aug;180(2):144-54. doi: 10.1016/s0002-9610(00)00432-3.
BACKGROUND
Extracorporeal membrane oxygenation (ECMO) is a supportive therapy used for severe acute respiratory distress syndrome (ARDS). We present outcome, clinical parameters, and complications in a cohort of 245 ARDS patients of whom 62 were treated with ECMO.
METHODS
Data of all ARDS patients were prospectively collected between 1991 and 1999. Outcome and clinical parameters of patients treated with and without ECMO were evaluated.
RESULTS
One hundred thirty-eight patients were referred from other hospitals, 107 were primarily located in our hospital. About one fourth of these patients were treated with ECMO. The survival rate was 55% in ECMO patients and 61% in non-ECMO patients.
CONCLUSIONS
ECMO is a therapeutic option for patients with severe ARDS, likely to increase survival. However, a randomized controlled study proving its benefit is still awaited. Until the development of a causal or otherwise superior therapy ECMO should be used in selected patients.
背景
体外膜肺氧合（ECMO）是用于治疗严重急性呼吸窘迫综合征（ARDS）的一种支持性疗法。我们报告了245例ARDS患者的治疗结果、临床参数及并发症情况，其中62例接受了ECMO治疗。
方法
前瞻性收集了1991年至1999年间所有ARDS患者的数据。对接受和未接受ECMO治疗的患者的治疗结果及临床参数进行了评估。
结果
138例患者由其他医院转诊而来，107例最初在我院就诊。这些患者中约四分之一接受了ECMO治疗。接受ECMO治疗患者的生存率为55%，未接受ECMO治疗患者的生存率为61%。
结论
ECMO是重度ARDS患者的一种治疗选择，可能会提高生存率。然而，仍有待一项随机对照研究来证实其益处。在有因果关系或其他更优疗法出现之前，应在选定患者中使用ECMO。
Zotero 插件